نتائج البحث - P.V. Plourde

  • يعرض 1 - 2 نتائج من 2
تنقيح النتائج
  1. 1
    Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression on prior therapies: ELAINE 2

    Open-label, phase II, multicenter study of lasofoxifene plus abemaciclib for treating women with metastatic ER+/HER2− breast cancer and an ESR1 mutation after disease progression o... حسب Senthil Damodaran, Ciara C. O’Sullivan, Ahmed Elkhanany, Ian C. Anderson, Minal Barve, Sibel Blau, Mathew Cherian, Julio A. Peguero, Matthew P. Goetz, P.V. Plourde, David Portman, H.C.F. Moore

    منشور في 2023
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:
  2. 2
    Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial

    Lasofoxifene versus fulvestrant for ER+/HER2− metastatic breast cancer with an ESR1 mutation: results from the randomized, phase II ELAINE 1 trial حسب Matthew P. Goetz, N.A. Bagegni, Gerald Batist, Adam Brufsky, Massimo Cristofanilli, Senthil Damodaran, B. Daniel, Gini F. Fleming, William J. Gradishar, Stephanie L. Graff, Maria T. Grosse Perdekamp, Erika Hamilton, Sayeh Lavasani, Alvaro Moreno‐Aspitia, Tracey L. O’Connor, Timothy Pluard, Hope S. Rugo, Sarah Sammons, Lee S. Schwartzberg, Daniel G. Stover, Gregory A. Vidal, G. Wang, Ellen Warner, Rinat Yerushalmi, P.V. Plourde, David Portman, Einav Nili Gal‐Yam

    منشور في 2023
    احصل على النص الكامل احصل على النص الكامل
    Artigo
    أضف إلى المفضلة
    محفوظ في:

أدوات البحث: